NextGen Sciences this week announced a series of new management appointments as part of its restructuring to focus on the cancer and central nervous system protein biomarker business.
Neal Siegel was appointed to the newly created position of director of assay development; Glenn Barney was appointed vice president of business development; and Hiroshi Saito was appointed director of marketing.
Siegel previously worked at Sword Diagnostics and Abbott Laboratories. Barney previously worked at Decision Biomarkers. Saito joins the company from online marketing agency Optiem LLC.
Integrated Diagnostics said this week that it has appointed Jay Moyes to its board of directors.
Moyes was previously the chief financial officer of molecular diagnostics firm XDx as well as Myriad Genetics and agricultural biotech firm Genmark. He is also director and chair of the audit committees of Osiris Therapeutics and BioCardia.
The Scripps Research Institute has named Michael Marletta to succeed long-time Scripps president Richard Lerner, who plans to continue his research at the institute after stepping down from the lead position.
Marletta was the chair of the chemistry department and a professor in the molecular and cell biology department at The University of California-Berkeley. He is also a former MacArthrur Fellowship winner. Lerner has led the institute for 25 years.